Form 4: Voyager Therapeutics CEO Sells Shares

Voyager Therapeutics CEO Alfred Sandrock sold 11,511 shares of common stock for $3.87 per share, a transaction related to tax withholding obligations upon vesting of restricted stock units.

Summary

• Alfred Sandrock, President and CEO of Voyager Therapeutics, Inc., reported a transaction involving the sale of 11,511 shares of common stock.
• The sale occurred on April 2, 2026, with shares sold at a weighted average price of $3.87.
• These shares were sold to cover tax withholding obligations related to the vesting of restricted stock units on April 1, 2026.
• The transaction was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on May 12, 2025, indicating it was not a discretionary trade.
• Following the transaction, Sandrock beneficially owns 472,549 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a sale of stock by the CEO, it is clearly defined as a non-discretionary transaction under a pre-established plan to cover tax obligations, which is a routine event.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, demonstrating adherence to pre-determined trading strategies and potentially mitigating insider trading concerns.
• The sale was specifically to cover tax obligations arising from vested restricted stock units, a common and expected event for executives.
• Sandrock retains a significant beneficial ownership of 472,549 shares, indicating continued substantial investment in the company.

Negatives

• A portion of the CEO's holdings was sold, which could be perceived negatively by the market, despite the planned nature of the transaction.

Risks

• The filing does not explicitly mention any new or emerging risks.
• The sale of shares by a key executive, even if planned, could be interpreted by some investors as a lack of confidence, although the context suggests otherwise.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the ranges set forth upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executives and directors, detailing changes in their beneficial ownership. Such transactions, especially those under Rule 10b5-1 plans, are common for managing personal finances and tax obligations while adhering to insider trading regulations. The specific price and volume in this filing are typical for such planned sales.

Stakeholder Impact

• Shareholders: The sale is planned and executed under a 10b5-1 plan to cover tax liabilities, minimizing the perception of negative insider sentiment. However, any stock sale by a CEO can be a point of observation for investors.
• Employees: The transaction is related to equity compensation (vesting of RSUs), which is a standard component of executive compensation structures.
• Management: The transaction confirms the CEO's adherence to company policies and SEC regulations regarding insider trading and disclosure.

Next Steps

• The reporting person may provide further details on specific sale prices upon request from the SEC, security holders, or the company.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Form 4, Insider Trading, Stock Sale, CEO, Restricted Stock Units, Rule 10b5-1, Beneficial Ownership, Tax Withholding